Abstract Search

ea0089o1 | Other | NANETS2022

Efficacy and Toxicity of Anti-Vascular Endothelial Growth Factor (VEGF) Receptor Tyrosine Kinase Inhibitors (TKIs) in Neuroendocrine Tumors (NETs) – A Systematic Review and Meta-Analysis

Das, MD, MSCI Satya , Phillips, MSPH Sharon , M Lebeck Lee, MD Cody , Agarwal, MD, MSCI Rajiv , Bergsland, MD Emily , Strosberg, MD Jonathan , A. Chan, MD, MPH Jennifer , LaFerriere, MLIS Heather , A. Ramirez, DO Robert , Berlin, MD Jordan , Arvind Dasari, MD, MS and

Background: Although anti-VEGF RTKIs have been tested in patients with NETs over the last 2 decades, no study to date has benchmarked efficacy and toxicity of these drugs in this patient population.Methods: A literature search was performed to identify all phase II and phase III studies of anti-VEGF RTKIs in patients with NETs published between January 1, 2000 July 31, 2021. Major trial databases (e.g. Medline, EMBASE, Cumulative Index of Nursing ...

0 shares

Endocrine Abstracts

Efficacy and Toxicity of Anti-Vascular Endothelial Growth Factor (VEGF) Receptor Tyrosine Kinase Inhibitors (TKIs) in Neuroendocrine Tumors (NETs) – A Systematic Review and Meta-Analysis

BiosciAbstracts